adenopathy and immunophenotype are also prognostic (6,8,10,12,13). Periodic assessment of treatment response provides an indication of the sensitivity of leukemic cells to chemotherapy (14), so accurate and sensitive determination of treatment response i.e. minimal residual disease (MRD) is a powerful predictor of clinical outcome in childhood ALL (13, 15 ). In the current study, we aimed at evaluating the impact of the presenting features on the treatment outcome, overall and disease free survival rates of children with de novo ALL who presented at the Pediatric Oncology Department, South Egypt Cancer Institute, from January 2008 to January 2014. .
Methods:
From January 2008 to January 2014, 172 pediatric patients with de novo ALL, 2-15 years old were prospectively analyzed for treatment outcome and survival rates according to the presenting clinical and laboratory features. The study was approved by the local ethical committee and informed consent was taken from the patients' guardians. All patients underwent the standard diagnostic workup of ALL. The diagnosis of ALL was based on both the morphologic and cytochemical examination of bone marrow (BM) smears as well as on the immunophenotyping (IPT) of the leukemic blast cells using multicolor flow cytometry. Lumbar puncture for cerebrospinal fluid (CSF) examination to determine the CNS status was also done for all patients. The CNS status of each patient was defined as follows: (i) CNS1, no identifiable blast cells in a non-traumatic CSF; (ii) CNS2, < 5 WBC/μL with identifiable blast cells in a non-traumatic CSF; (iii) CNS3, ≥ 5 WBC/μL with identifiable blast cells in a non-traumatic CSF or the presence of cranial nerve palsy (3,16). A traumatic lumbar puncture (≥10 erythrocytes/µL) that includes blasts at diagnosis has also been associated with increased risk of CNS relapse (17), Some clinical trial groups have approached CNS2 and traumatic lumbar puncture by utilizing more intensive therapy, primarily additional doses of intrathecal therapy during induction (18). Other groups have not altered therapy based on CNS2 status (19). Bulky extramedullary disease was defined by either: a mediastinal mass > 33% of the intrathoracic dimension at the level of the fifth thoracic vertebra, lymphadenopathy > 3 cm in dimension for a single lymph node or > 5 cm in dimension for a group of contiguous lymph nodes, or splenomegaly in the supine position with the spleen tip palpated below the umbilicus (20).
Risk Classification: Patients were stratified as standard risk (SR) or high risk (HR) based on the COG ALL Risk Classification System (7,9,13). SR criteria were Bcell precursor with age 2-< 10 years at presentation, WBC count < 50x109/µL, and CNS1 status. All other patients were classified as HR.
Treatment Protocol: The patients were treated on the modified TXIIIB protocol adopted from St. Jude Children Research Hospital (SJCRH) ( Table 1) (14) . We extended the continuation treatment for all the males to be 146 weeks (total 3 years of chemotherapy) as recommended by many pediatric ALL groups (1,11,15). The extended weeks constituted of monthly vincristine (1.5 mg/m2) intervened by weekly intramuscular methotrexate (40 mg/m2) and daily mercaptopurine (60 mg/m2).
Response and Relapse Criteria: At the end of induction phase, full clinical assessment and BM aspiration (BMA) for cytomorphologic assessment of remission were done for all patients. Complete remission was defined as the absence of leukemic blasts in peripheral blood and CSF and less than 5% blasts on BMA smear and no evidence of extramedullary disease (1,11). Relapse was defined as recurrence of ≥ 25% lymphoblasts in BM or localized leukemic infiltrates at any site (1,11).
Statistical Analysis: Overall Survival (OS) was defined as the length of time from the date of diagnosis that patients are still alive. Disease Free survival (DFS) was defined as the length of time that the patient survives in clinical and laboratory remission from the date of diagnosis. Cox regression analysis was done for multivariate estimation of the impact of the different clinical features on the overall survival and DFS.
Results:
The mean duration of follow up of the patients accrued to our study was 19.1±13.8 months (range 0.5-56.7 months). The patients' characteristics and the treatment outcome were as follows:
Patients' Characteristics: The presenting clinical and laboratory characteristics of the 172 patients are reported in Table 2 . The median age at diagnosis was 5 years (range 2 to 15 years) and male to female ratio was 1.45:1.
Treatment Outcome: Of the total 172 patients; 113 (65.7%) continued in remission, 26 relapsed (18 isolated medullary, 6 isolated CNS and 2 combined medullary and CNS relapses), 19 died in remission (18 from sepsis and one from methotrexate toxicity) and 14 abandoned the treatment. The 4-year overall (OS), disease free-(DFS) and event-free (EFS) survival rates (±SE) were 89% (±2), 83% (±2.5) and 73.8% (±2.7) respectively ( Figure 1 ).
Prognostic Clinical Characteristics: On analysis of the impact of different clinical and laboratory characteristics on the treatment outcome, OS and DFS rates, we found that age, bulky disease, mediastinal adenopathy and CNS status all had significant effect on the treatment outcome and survival rates (Table 2, Figure 2 ). 
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Discussion:
Certain clinical and laboratory characteristics at presentation in pediatric ALL were significantly predictive of treatment outcome and survival rate. In the current study, we tried to determine the features that predict the outcome of the pediatric patients with de novo ALL who presented to our department at South Egypt Cancer Institute from January 2008 to January 2014. The age at presentation was the simplest clinical criterion that can be used to judge the prognosis of the patients (13). Patients with favorable age group (2 -< 10 years) showed significantly higher DFS (87% vs.
71.1% P 0.03) and lower relapse rates (11% vs. 26.8% P 0.02) than patients with unfavorable age group (≥ 10 years). Favorable age at presentation is usually associated with better outcome and survival rates than the unfavorable age owing to its association with favorable biologic features (22,23) while unfavorable age is known to be associated with higher WBC count, T-cell phenotype and unfavorable biologic features (24). However, the treatment outcome of the patients who present at age ≥ 10 years old had improved dramatically over years owing to the exploitation of the AbdelHamid et al. SECI Oncology 2015 DOI: 10.18056/seci2015.6 P a g e 6 of 9 more intensive pediatric chemotherapy regimens rather than the adult ones (25-28).
Female gender was associated with slightly higher but insignificant continuous complete remission (67.1% vs. 64.7% in males P 0.7), DFS and EFS rates (84% vs. 82.2% and 75.7% vs. 72.5% in males P 0.6 and 0.5 respectively than males). Male gender was also associated with higher relapse rates (15.7% vs. 14.3% in girls P 0.8). Some studies still show that the prognosis of ALL in girls is slightly better than for boys owing to the higher testicular relapse rate in boys (29-31) while other studies showed that the prognosis of boys was approaching that of girls (19). Differences in drug metabolism secondary to polymorphisms in enzyme involved in xenobiotic metabolism in boys contribute to their sensitivity to anti-leukemic drugs (32).
Our patients who presented with bulky disease showed a significantly higher relapse rate (36% vs. 11.6% P 0.001) and lower DFS rate than those who had no bulky features (59% versus 87% P 0.001) (table 2) owing to its association with other aggressive risk factors as unfavorable age, T-cell phenotype, mediastinal adenopathy and slower response to chemotherapy as we found in our study.
For patients who presented mediastinal adenopathy, we encountered a relatively higher percentage of mediastinal adenopathy at presentation (9.9%) than other studies (33,34) and those patients showed significantly lower DFS rate (64.3% vs. 84.9% P 0.03) than those who had no mediastinal adenopathy at presentation. They also had remarkably lower but insignificant continuous remission rate (47.1% vs. 67.7% P 0.08) and higher relapse rate (29.4% vs. 13.5% P 0.08) than those who had no mediastinal adenopathy at presentation. The less favorable outcome can be partly attributed to the association of mediastinal adenopathy with other aggressive prognostic features including older age, high initial WBC count, T-cell phenotype and bulky disease. Möricke et al., 2010 showed that, in BFM-86 trial, mediastinal adenopathy at presentation was a criterion for high risk assignment but not in the subsequent trials while Attarbaschi et al., 2002 reported that mediastinal adenopathy as well as its rate of regression lack prognostic significance.
The presence or absence of CNS leukemia (CNS3) at diagnosis has prognostic significance, as these patients are at a higher risk of treatment failure (both within the CNS and systemically) owing to its association with other aggressive risk factors and bad biologic features (37) (38) (39) . CNS is considered as a sanctuary site and both high dose systemic chemotherapy as well as CNS directed therapy are necessary in order to control the CNS disease (40, 41) . The presence of CNS leukemia in the ALL patients who accrued to our study was associated with a significantly higher relapse rate (50% vs. 13.9% P 0.02) than patients with no CNS leukemia.
WBC count at diagnosis was incorporated in the first risk stratification of pediatric patients with ALL at diagnosis and a count of 50,000/µL is generally used as an operational cutoff point between better and poorer prognosis (12). Patients with unfavorable WBC count (≥ 50.000/μL) at diagnosis showed a remarkable but insignificant higher relapse rate (20% vs. 13.1% P 0.2), lower remission rate (58% vs. 68.9% P 0.17) and lower DFS (77.8% vs. 85.2% P 0.2) rate than those with favorable presenting WBC count (<50.000/μL). The insignificant results are related to the short duration of follow up of the patients in this study (median duration 19 months). Another contributing factor to the inferior outcome of these patients was the association of unfavorable WBC count at diagnosis with other aggressive risk factors as T-cell phenotype, bulky extramedullary disease, mediastinal adenopathy and CNS leukemia. Vaitkevičienė et al., 2011 showed that high WBC at diagnosis was a modifying factor for the treatment outcome of the patients with B-cell phenotype but not for those with T-cell phenotype and is associated with a slower end induction remission rate.
The pediatric ALL patients B-cell phenotype included in this study had slightly and insignificant higher continuous complete remission rate than those with T-cell phenotype (66.9% vs. 60.6% P 0.5). We encountered higher percentage of pre-B cell (58.7%) subtype which -in some reports-is associated with t(1;19) in 25% of the occasions which requires more intensive treatment and confers inferior outcome (43) . Also, the outcome of the patients with B-cell ALL can be modified by age and WBC count at diagnosis, presence of CNS leukemia (18,43,37-39) and presence of other unfavorable biologic features (35, 42, 44) . By analysis, around 67.6% of our patients with B-cell phenotype had one or more unfavorable clinical or laboratory features that contributed to the poor outcome. However, patients with T-cell phenotype showed markedly but insignificant higher relapse rate (27.3% vs. 12.2% P 0.15) and lower DFS rate (70% vs. 87.5% P 0.09) than those with B-cell phenotype. Gaynon et al., 2010 and Möricke et al., 2010 reported higher relapse rate and lower both DFS and EFS rates for patients with T-cell phenotype and attributed this inferior outcome to the its association with other aggressive prognostic factors as older age, higher initial WBC count, bulky extramedullary disease and mediastinal adenopathy. They also reported that with appropriately intensive therapy, T-cell ALL have an outcome approaching that of B-cell ALL.
Conclusion:
Certain clinical and laboratory criteria at diagnosis of pediatric patients with ALL can have a significant impact on the treatment outcome and survival rates of these children. Of these, are the presentations with bulky extramedullary disease and/or mediastinal adenopathy and presence of CNS leukemia necessitating aggressive treatment. WBC count at diagnosis is independent risk factor that can modify the outcome of other factors. Gender of the patient has no longer a significant impact on the treatment outcome and survival of the pediatric patients with ALL.
